Citius Pharmaceuticals shares surge 30.77% after-hours after launching LYMPHIR, its first FDA-approved cancer immunotherapy for CTCL, and securing $61 million in financing.

Citius Pharmaceuticals, Inc. surged 30.77% in after-hours trading following the launch of its FDA-approved cancer immunotherapy, LYMPHIR, in December 2025. The drug, the first new systemic therapy for cutaneous T-cell lymphoma (CTCL) since 2018, marked a pivotal commercial milestone. The company also secured $61 million in strategic financings (including $25 million by Citius Pharma and $36 million by Citius Oncology), bolstering cash reserves to $4.3 million and supporting LYMPHIR’s U.S. and international distribution. Additionally, LYMPHIR’s inclusion in NCCN guidelines and a permanent HCPCS J-code for reimbursement further signaled commercial viability. These developments, alongside preparations for AI-driven marketing and partnerships with leading wholesalers, likely drove the sharp post-market rally, reflecting optimism about LYMPHIR’s market potential and the company’s financial stability.